Palatin Technologies shares jump 10.93% after-hours on focus on peptide therapies and potential biotech breakthroughs.

Palatin Technologies surged 10.93% in after-hours trading, likely driven by renewed investor interest in its pipeline of peptide-based therapies, particularly for dry eye and sexual dysfunction. Recent coverage highlighted Palatin’s focus on innovative treatments targeting unmet medical needs, with its lead product Vyleesi already FDA-approved and PL9643 in Phase 3 trials. The article emphasized the global appeal of the company’s approach, especially in the U.S. and Europe, and suggested that positive clinical readouts could trigger partnerships or broader market expansion. As a speculative biotech play, the stock appears to be reacting to speculative upside potential amid favorable market sentiment toward peptide therapeutics and potential regulatory milestones.